Pfizer Inc.
PFE | NYSE
$30.52
+$0.57 (+1.90%)
At close: Oct 30, 2026, 4:00 PM ET
$30.45
-$0.07 (-0.22%)
After-hours:
Oct 30, 2026, 7:55 PM ET
Company Profile
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Albert Bourla | Chairman of the Board & Chief Executive Officer |
| David Denton | Executive Vice President & Chief Financial Officer |
| Dennis Hancock | Executive VP & Chief Information Officer |
| Douglas Lankler | Executive Vice President & Chief Legal Officer |
| Aamir Malik | Executive Vice President & Chief U.S. Commercial Officer |
| Cecile Guegan | Interim CFO & Executive VP |
| Chris Boshoff FMedSci | Chief Scientific Officer and President of Research & Development |
| Francesca DeMartino | Chief Investor Relations Officer |
| Jeffrey Settleman | Chief Scientific Officer of Oncology |
| Jennifer Damico | Senior Vice President, Controller & Principal Accounting Officer |
| Michael S. Vincent | Senior Vice President and Chief Scientific Officer of Inflammation & Immunology |
| Payal Sahni Becher | Chief People Experience Officer & Executive Vice President |
Pfizer Inc.
| Country | United States |
| IPO Date | Jun 1, 1972 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,000 |
| CEO | Albert Bourla |
Contact Details
66 Hudson Boulevard East New York City,
New York 10001-2192 United States
Stock Details
| Ticker Symbol | PFE |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000078003 |
| CUSIP Number | 717081103 |
| ISIN Number | US7170811035 |
| SIC Code | 2834 |
Recent News
- 1 day ago / fool.comPfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?
- 2 days ago / 247wallst.com$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
- 2 days ago / seekingalpha.comPfizer: Reality Check Ahead Of Earnings
- 2 days ago / 247wallst.comPfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?
- 3 days ago / zacks.comExploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPS
- 4 days ago / zacks.comPfizer (PFE) Stock Sinks As Market Gains: Here's Why
- 4 days ago / zacks.comPfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?
- 5 days ago / benzinga.comPfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients
- 5 days ago / zacks.comPfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
- 6 days ago / businesswire.comPfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
Add to Watchlist
Select watchlists to add or remove PFE